For treating the heteroaryl formonitrile HCN of disease
AU2015202475A1
Piperidine derivatives as nk1 antagonists
AU2014271269A1
Intravenous formulations of neurokinin-1 antagonists
AU2012216435A1
Piperidine derivatives as NK1 antagonists
CN103269585A
Hypersulfated disaccharides to treat elastase related disorders
US2011245197A1
Hypersulfated glucopyranosides
CN102711463A
Hypersulfated disaccharide formulations
KR20120060215A
Intravenous formulations of neurokinin-1 antagonists
AU2010253797A1
Peptoid ligands for isolation and treatment of autoimmune T-cells
CN102203062A
Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
CN104447510A
Process and intermediates for synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one
US2010104637A1
Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom
SG170838A1
Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}- methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor
